Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

May 15, 2024

LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024.

The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage draft, performance of new direct to physician sales force, April launch of U.S. Food and Drug Administration (“FDA”) De Novo authorized kidneyintelX.dkd, and release of new real-world outcomes evidence. Optimization of shareholder value continues with year over year significant expense reductions, completion of equity financing, and the initiation of a strategic sale process.

Highlights include:

  • KidneyIntelX included as only biomarker test for prognostic risk assessment in landmark update of international clinical practice guidelines (
  • Medicare Local Coverage Determination draft issued for FDA-authorized kidneyintelX.dkd by Medicare contractor National Government Services (NGS) with final issuance expected in the near term
  • Formal launch of the FDA-authorized kidneyintelX.dkd in April 2024
  • Customer experience improvements implemented including simplified physician order requisition, increased patient access to national blood draw network, revamped marketing and education materials
  • New primary care sales force completed its first quarter of operations with a 33% quarter over quarter increase in independent primary care physician test order volume during the three months ended March 31, 2024
  • Appointed Howard Doran to president concurrent with organizational changes to focus to accelerating sales and marketing of FDA-authorized kidneyintelX.dkd test
  • Formal strategic sale process initiated with multiple potential acquirers now in discussions
  • Completed common stock equity financings raising aggregate gross proceeds of $13.5 million (including post-period activity)
  • Continued operating expense reduction with 50% year-over-year reduction in head count and approximately 40% total lower operating costs
  • With FDA and clinical guidelines achieved, process initiated for potential ex-U.S. partners to improve non-dilutive company cash position and expand incremental sales opportunities
  • U.S. government added the FDA-authorized kidneyintelX.dkd to 10-year Government-wide Acquisition Contract (GWAC) at a price of $950 per reportable result. The contract covers tests provided by any government healthcare facility
  • Total volume of 806 tests during the quarter, of which 82% were billable

Third Quarter 2024 Financial Results
During the three months ended March 31, 2024, the Company recognized $0.5 million of revenue, compared to $0.7 million for the three months ended March 31, 2023. Cost of revenue for the three months ended March 31, 2024 and 2023, was $0.6 million.

Operating expenses for the three months ended March 31, 2024 were $6.5 million, compared to $11.0 million during the prior year period. Operating cash burn in the fiscal third quarter was $4.9 million, nearly 40% lower than the fiscal second quarter and a 50% reduction from the year ago period.

Within operating expenses, research and development expenses were $2.2 million for the three months ended March 31, 2024, decreasing by $1.7 million from $3.9 million for the three months ended March 31, 2023. The decrease was attributable to a $1.3 million decrease related to external R&D projects and studies with Mount Sinai, Wake Forest and Joslin, a decrease of $0.3 million in compensation and related benefits, and a $0.1 million decrease in other operating expenses.

General and administrative expenses were $3.9 million for the three months ended March 31, 2024, decreasing by $3.2 million from $7.1 million for the three months ended March 31, 2023. The decrease was driven by even further cost cutting measures, which resulted in a $2.6 million decrease in compensation and related benefits, a $0.3 million decrease in other operating expenses, and a $0.3 million decrease in insurance costs.

Net loss was $7.7 million for the three months ended March 31, 2024, compared with $12.1 million for the prior year period.

Cash and cash equivalents totaled $4.7 million as of March 31, 2024.

The Company will host a corresponding conference call and live webcast today to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. EDT / 1:30 p.m. BST.

Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Webcast Registration link:

For further information, please contact:

Renalytix plc
James McCullough, CEOVia Walbrook PR
Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea 
Investec Bank plc (Joint Broker)Tel: 020 7597 4000
Gary Clarence / Shalin Bhamra 
Walbrook PR LimitedTel: 020 7933 8780 or
Paul McManus / Alice WoodingsMob: 07980 541 893 / 07407 804 654
CapComm Partners 
Peter DeNardo
Tel: 415-389-6400 or

About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the commercial prospects of KidneyIntelX, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, the rate of testing with KidneyIntelX in health care systems, expectations and timing of announcement of real-world testing evidence, the potential for KidneyIntelX to be approved for additional indications, the Company’s expectations regarding the timing and outcome of regulatory and reimbursement decisions, the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes, the Company’s expectations and guidance related to partnerships, testing volumes and revenue for future periods, the Company’s expectations regarding the Company’s ability to obtain and maintain intellectual property protection for its diagnostic products and the Company’s ability to operate its business without infringing on the intellectual property rights of others, and the forecast of the Company’s cash runway and the implementation and potential for additional financing activities and cost-saving initiatives. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on the Company’s forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; the Company has only recently commercially launched KidneyIntelX; and risks relating to the impact on the Company’s business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of its annual report on Form 10-K filed with the SEC on September 28, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC on November 14, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024 filed with the SEC on February 14, 2024 and other filings the Company makes with the SEC from time to time. All information in this press release is as of the date of the release, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

  For the Three Months Ended March 31,  For the Nine Months Ended March 31, 
(in thousands, except share data) 2024  2023  2024  2023 
Revenue $535  $724  $1,703  $2,885 
Cost of revenue  601   603   1,583   2,010 
Gross profit (loss)  (66)  121   120   875 
Operating expenses:            
Research and development  2,216   3,943   8,228   11,026 
General and administrative  3,854   7,095   15,252   22,155 
Impairment loss on property, equipment and other long-lived assets  417      723    
Performance of contract liability to affiliate           (19)
Total operating expenses  6,487   11,038   24,203   33,162 
Loss from operations  (6,553)  (10,917)  (24,083)  (32,287)
Equity in net losses of affiliate           (9)
Foreign currency gain (loss), net  15   (461)  215   238 
Fair value adjustment to VericiDx investment  40   129   (205)  (1,070)
Fair value adjustment to convertible notes  (1,196)  (1,168)  (2,517)  (1,898)
Other (expense) income, net  (49)  310   212   521 
Net loss before income taxes  (7,743)  (12,107)  (26,378)  (34,505)
Income tax (expense) benefit     1   (4)  2 
Net loss $(7,743) $(12,106) $(26,382) $(34,503)
Net loss per ordinary share—basic $(0.08) $(0.14) $(0.27) $(0.44)
Net loss per ordinary share—diluted $(0.08) $(0.14) $(0.27) $(0.44)
Weighted average ordinary shares—basic  97,654,961   85,560,783   98,184,650   78,366,984 
Weighted average ordinary shares—diluted  97,654,961   85,560,783   98,184,650   78,366,984 
Other comprehensive income (loss):            
Changes in the fair value of the convertible notes $155  $593  $230  $70 
Foreign exchange translation adjustment  21   505   (338)  6 
Comprehensive loss $(7,567) $(11,008) $(26,490) $(34,427)



(in thousands, except share and per share data)   March 31, 2024  June 30, 2023 
Current assets:        
Cash and cash equivalents   $4,704  $24,682 
Accounts receivable    554   776 
Prepaid expenses and other current assets    1,082   1,424 
Total current assets    6,340   26,882 
Property and equipment, net    230   1,027 
Right of Use Asset       159 
Investment in VericiDx    1,060   1,460 
Other Assets    1,139   1,101 
Total assets   $8,769  $30,629 
Liabilities and Shareholders’ Equity        
Current liabilities:        
Accounts payable   $2,101  $1,485 
Accounts payable – related party    3,027   1,451 
Accrued expenses and other current liabilities    4,273   6,644 
Accrued expenses – related party    1,060   1,963 
Current lease liability    78   130 
Convertible notes-current    4,449   4,463 
Total current liabilities    14,988   16,136 
Convertible notes-noncurrent    4,892   7,485 
Noncurrent lease liability       41 
Total liabilities    19,880   23,662 
Commitments and contingencies (Note 10)        
Shareholders’ equity:        
Ordinary shares, £0.0025 par value per share: 128,042,743 shares    
authorized; 119,916,187 and 93,781,478 shares issued and
outstanding at March 31, 2024 and June 30, 2023, respectively
    368   286 
Additional paid-in capital    194,786   186,456 
Accumulated other comprehensive loss    (1,558)  (1,450)
Accumulated deficit    (204,707)  (178,325)
Total shareholders’ (deficit) equity    (11,111)  6,967 
Total liabilities and shareholders’ (deficit) equity   $8,769  $30,629 



  For the Nine Months Ended March 31, 
(in thousands) 2024  2023 
Cash flows from operating activities:      
Net loss $(26,382) $(34,503)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization  304   388 
Impairment loss on property, equipment and other long-lived assets  723    
Stock-based compensation  1,291   2,358 
Equity in losses of affiliate     9 
Reduction of Kantaro liability     (55)
Fair value adjustment to VericiDx investment  205   1,070 
Unrealized foreign exchange loss     327 
Realized loss on sale of ordinary shares in VericiDx  94    
Realized foreign exchange gain  (144)   
Fair value adjustment to convertible debt, net interest paid  2,255   1,898 
Non cash lease expense  67   78 
Changes in operating assets and liabilities:      
Accounts receivable  222   154 
Prepaid expenses and other current assets  310   (77)
Accounts payable  617   358 
Accounts payable – related party  1,576   370 
Accrued expenses and other current liabilities  (2,519)  2,704 
Accrued expenses – related party  (904)  (485)
Deferred revenue     (46)
Net cash used in operating activities  (22,285)  (25,452)
Cash flows from investing activities:      
Purchase of equipment  (3)   
Payment for long term deferred expense     (59)
Net cash used in investing activities  (3)  (59)
Cash flows from financing activities:      
Payment of convertible notes principal  (1,660)  (3,262)
Proceeds from issuance of ordinary shares in Private Placement  5,072   20,296 
Payment of offering costs  (1,044)  (666)
Proceeds from purchase of ordinary shares under employee share
purchase plan
  93   116 
Net cash provided by financing activities  2,461   16,484 
Effect of exchange rate changes on cash  (151)  721 
Net decrease in cash and cash equivalents  (19,978)  (8,306)
Cash and cash equivalents, beginning of period  24,682   41,333 
Cash and cash equivalents, end of period $4,704  $33,027 
Supplemental noncash investing and financing activities:      
Cash paid for interest on convertible debt $249  $